Can-Fite BioPharma (CANF) Announces $7.5M Share Offering at $5.50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Grand Canyon Education places CFO on leave amid stock trade probe
- Funds sell $44bn in semiconductors on AI concerns
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
January 11, 2023 9:04 AM ESTPETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases (Can-Fite or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000 of the Companys American Depositary Shares (ADSs) (or ADS equivalents in lieu thereof), at a purchase price of $5.50 per ADS, in a registered direct offering. In a concurrent private placement, Can-Fite has also agreed to issue and sell... More
